BIAL sells allergic immunotherapy business
BIAL has reached an agreement with the German company Roxall to sell its allergic immunotherapy business unit, known as BIAL Aristegui, dedicated to the development, production and commercialization of anti-allergic vaccines and diagnostic tests. This operation includes the commercial areas dedicated to allergology in Spain, Portugal and Italy, which represented 7% of BIAL's global turnover in 2016, as well as the R&D and industrial unit located in Bilbao, involving around 100 employees who will become integrated into Roxall.
Portugal’s Prime Minister and the Ministers of Health and Economy visited BIAL
The visit to the Research and Development Center, in Trofa, took place in the scope of an investment contract. BIAL has just signed an investment contract with the Portuguese Government of over €37 Mio, to be carried out until December 2018. The Prime Minister, António Costa, and the Ministers of Health and Economy attended the contract signature ceremony after visiting BIAL’s R&D Department.
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.